Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Jana Biermann

Forskare

Jana Biermann
Forskare
jana.biermann@gu.se


Avd för onkologi vid Institutionen för kliniska vetenskaper (Mer information)
Sahlgrenska Universitetssjukhuset
413 45 Göteborg
0313428503
Besöksadress: Blå stråket 2 SU/Jubileusklin , 413 45 Göteborg

Om Jana Biermann

Doctoral theses - Tumour evolution and novel biomarkers in breast cancer

The public defence 2019-05-24

Link to doctoral theses short summary here on this profile page

Gene signature predicting clinical outcome in breast cancer patients
Breast cancer is the most common type of cancer in women with more than 2 million new cases and about 627,000 breast cancer-related deaths worldwide in 2018. Several gene signatures have been proposed to improve prognosis of breast cancer outcome and guide treatment decisions. Current treatment guidelines, however, primarily focus on established patient- and tumour-specific features.

- Using molecular biology and statistical models in addition to established clinical and pathological factors improves risk assessment of breast cancer patients. Being able to separate high-risk from low-risk patients can help to personalize treatment and avoid over- and under-treatment, says Jana Biermann, PhD candidate working on cancer genomics and bioinformatics at the Sahlgrenska Cancer Center.

Important to differentiate recurrent breast tumours from new primary tumours
Despite increasing survival rates, about 6-23 percent of breast cancer patients suffer from recurrences within five years of initial treatment indicating treatment failure. In clonal tumours, both tumours share similar clinicopathological and molecular features and aggressive treatment is required as the recurrent tumour probably contains resistant cells. It is highly important to distinguish clonally related tumours from independent tumours to provide the best treatment strategy for the patient.

- Currently, there is no consensus on how to define clonal relatedness between multiple tumours in the same patient. We compared different statistical methods and types of data and identified the Similarity Index (SI) as the most reliable tool to classify tumour clonality.

Ionizing radiation associated with increased genomic instability in breast tumours
The mammary gland is known to be highly sensitive to radiation, especially at a young age. In the years from 1920-1965, infants were treated with ionizing radiation for skin haemangioma and showed an increased risk of developing breast cancer later on. Ionizing radiation has been shown to induce genomic instability.

- We analysed breast tumours from the Swedish haemangioma cohort for genomic instability. Patients with higher absorbed doses to the breast exhibited increased genomic instability compared to patients exposed to lower doses. Radiation-induced genomic instability might explain how ionizing radiation at a young age can lead to increased breast cancer risk in the subsequent decades.

An important discovery regarding the use of radiotherapy
- The fascinating part is that we could detect a biological connection between genomic instability and radiation exposure in human samples, as most studies in this field are restricted to animal and cell culturing experiments. This demonstrates the long-term effects of ionizing radiation on the human body, which is an important factor to consider regarding the use of radiotherapy.

Kort svensk sammanfattning
Bröstkörteln är känd för att vara mycket känslig för joniserande strålning, särskilt hos unga. Under åren 1920–1965 behandlades spädbarn med joniserande strålning för hudhemangiom och uppföljning har visat en ökad risk att utveckla bröstcancer senare i livet. Joniserande strålning har visat sig inducera genomisk instabilitet.

- Vi analyserade brösttumörerna från patienter i den svenska hemangiomkohorten för genomisk instabilitet. Patienter med högre absorberade doser i bröstet uppvisade ökad genomisk instabilitet jämfört med patienter som fick lägre doser. Strålningsinducerad genomisk instabilitet kan vara förklaringen till att joniserande strålning i ung ålder kan leda till ökad risk för bröstcancer under de följande decennierna.

Sammanfattningsvis belyser detta arbete hur molekylärbiologi och statistiska modeller kan öka möjligheterna till riskbedömningar i tillägg till redan etablerade kliniska och patologiska faktorer. Detta gör att riskbedömningarna kan förbättras och med hjälp av det kan strategierna för bröstcancerbehandling anpassas till det bättre.

 

Senaste publikationer

Clonal relatedness in tumour pairs of breast cancer patients.
Jana Biermann, Toshima Z Parris, Szilard Nemes, Anna Danielsson, Hanna Engqvist et al.
Breast cancer research : BCR, Artikel i vetenskaplig tidskrift 2018
Artikel i vetenskaplig tidskrift

A novel 18-marker panel predicting clinical outcome in breast cancer
Jana Biermann, Szilard Nemes, Toshima Z Parris, Hanna Engqvist, Elisabeth Werner Rönnerman et al.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Artikel i vetenskaplig tidskrift 2017
Artikel i vetenskaplig tidskrift

Visar 1 - 10 av 15

2019

2018

Clonal relatedness in tumour pairs of breast cancer patients.
Jana Biermann, Toshima Z Parris, Szilard Nemes, Anna Danielsson, Hanna Engqvist et al.
Breast cancer research : BCR, Artikel i vetenskaplig tidskrift 2018
Artikel i vetenskaplig tidskrift

2017

A novel 18-marker panel predicting clinical outcome in breast cancer
Jana Biermann, Szilard Nemes, Toshima Z Parris, Hanna Engqvist, Elisabeth Werner Rönnerman et al.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Artikel i vetenskaplig tidskrift 2017
Artikel i vetenskaplig tidskrift

2016

Visar 1 - 10 av 15

Sidansvarig: Katarina Olinder Eriksson|Sidan uppdaterades: 2013-03-28
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?